In this episode, ‘Understanding Biologic Therapies in Psoriasis,’ the expert dermatologistsexplore the evolving landscape of biologic therapies in psoriasis, focusing on the key differences between therapeutic classes and the clinical importance of having multiple targeted treatment options. The faculty discussed how advances in the understanding of psoriasis pathophysiology, particularly the central IL-23/IL-17 inflammatory pathways have enabled the development of more precise and effective therapies compared with earlier biologics such as TNF-α inhibitors.

The panelists highlighted how first-generation biologics, while effective, were less targeted and associated with broader immune effects, requiring more extensive monitoring and consideration of off-target risks. As newer therapies have emerged, including IL-12, IL-23, and IL-17 inhibitors, clinicians have gained the ability to more selectively modulate the immune system. This has led to improvements in efficacy, safety, and overall treatment outcomes.

The faculty also examined the nuanced differences between targeting upstream versus downstream pathways, including variations in onset of action, durability of response, and potential effects on comorbid conditions such as inflammatory bowel disease. These distinctions underscore why multiple biologic classes are necessary, as no single therapy is optimal for all patients. They emphasized how a clearer understanding of disease biology enhances patient communication. By explaining psoriasis as a dysregulation of a specific immune pathway, clinicians can help patients better understand how targeted therapies work while reassuring them that broader immune function is preserved. Overall, this discussion reinforces the value of personalized treatment selection in modern psoriasis care.

The next episode in this series, ‘Treatment Selection in Psoriasis,’ features the panelists examining long-term data supporting sustained remission in psoriasis and how these findings influence clinical confidence in treatment durability. It also highlights how clinicians incorporate patient characteristics and real-world considerations when selecting biologic therapies to achieve long-term disease control.